

Compounds Specific for the Human  $\alpha_{1d}$  Adrenergic Receptor  
and Uses Thereof

Abstract of the Disclosure

This invention is directed towards a method of inhibiting  
5 activation of a human  $\alpha_{1d}$  adrenergic receptor which  
comprises contacting the receptor with a compound so as  
to inhibit activation of the receptor, wherein the  
compound binds selectively to a human  $\alpha_{1d}$  adrenergic  
receptor. This invention provides for a compound which  
10 binds selectively to a human  $\alpha_{1d}$  adrenergic receptor. The  
invention further provides a pharmaceutical composition  
comprising a therapeutically effective amount of the  
above-defined compounds and a pharmaceutically acceptable  
carrier. This invention further provides for a method of  
15 treating a subject afflicted with a disease which is  
susceptible to treatment by antagonism of the human  $\alpha_{1d}$   
adrenergic receptor which comprises administering to the  
subject an amount of the above defined compounds  
effective to treat the disease.

2025 RELEASE UNDER E.O. 14176